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Abstract: Recently, it has been shown that a truncated HCV core (HCcAg) variant, covering the first 
120 aa (HCcAg.120), interacts with plasmid DNA vaccine (pIDKE2), encoding the HCV structural 
proteins (HCcAg, E1 and E2). In the present work, HCcAg.120-pIDKE2 complexes, forming 
heterogeneous packaged structures, were visualized using a negative stain/rotary shadow technique. 
Interestingly, 72 hours after intramuscular injection of HCcAg.120-pIDKE2 complexes in Balb/c mice, 
E2 protein was immunolabeled in muscle cells. In fact, HCcAg.120-pIDKE2 complexes induced anti-
HCV humoral and cellular immune responses in mice when inoculated by both, parenteral or mucosal 
routes, although intranasal administration generally rendered weaker results. On the other hand, data 
demonstrated that Alum enhanced the HCV-specific IgG antibody production. However, the analysis 
of the HCV-specific cellular immune response showed that HCcAg.120-pIDKE2 delivered in PBS by 
the intramuscular route induced the strongest HCV-specific lymphoproliferative response, especially 
against E1 and induced viremia control in a vaccinia virus surrogate challenge model. These results 
support the use of HCcAg.120-pIDKE2 complexes in the rational design of therapeutic or preventive 
vaccine strategies against HCV infection. 
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INTRODUCTION 
 
  Hepatitis C virus (HCV) infection is considered a 
major health problem affecting an estimated 170 
million people worldwide
[1]. Approximately 50 to 80% 
of HCV patients develop chronic hepatitis, which may 
be complicated by cirrhosis and/or hepatocellular 
carcinoma
[1]. At present, there is no vaccine available to 
prevent HCV infection and current therapies are not 
optimal
[2]. Thus, prophylactic and therapeutic 
approaches to prevent liver damage caused by HCV 
infection are urgently needed.  
  HCV is a member of the Flaviviridae family with a 
positive strand RNA of 9.6 kb
[3]. The viral genome is 
translated into a single polyprotein of 3,000 amino 
acids in host cells. A combination of host and viral 
proteases are involved in polyprotein processing to give 
at least nine different proteins
[4,5]. The structural 
proteins of HCV are believed to comprise the core 
protein (HCcAg) and two envelope glycoproteins: E1 
and E2
[5].  
  Because HCV is an enveloped virus, neutralizing 
determinants   likely   reside   on   the   surface   of    the  
 
envelope. The envelope protein E2 of HCV contains 
highly variable sequences within the N-terminal region 
(HVR1), which are thought to contain neutralizing B-
cell epitopes
[6,7]. However, the role of neutralizing Abs 
in protective immunity against HCV infection is still 
uncertain
[6].  
  Studies in humans and chimpanzees have indicated 
that failure to generate multispecific cellular immune 
responses against HCV in the acute phase of infection 
is associated with chronicity
[8,9]. Conversely, patients 
with strong HCV-specific cellular immune responses 
have lower levels of viremia and these responses 
correlate with recovery
[10-12]. Of the cellular immune 
responses, the induction of Th1 type response, which 
has been linked to viral clearance in HCV, is probably 
important for a HCV vaccine
[13]. Therefore, an ideal 
HCV vaccine may need to induce strong humoral 
responses against the envelope proteins and to prime 
broad HCV-specific T helper (Th) and cytotoxic T 
lymphocytes (CTL) responses
[14].  
  Previously, it has been reported that a recombinant 
C-terminal truncated HCcAg (HCcAg.120) interacts in 
vitro with a plasmid DNA vaccine (pIDKE2) leading to  
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heterogenous virus-like particles (VLPs) formation
[15]. 
In addition, HCcAg.120 has recently been shown to 
enhance the immune response elicited by pIDKE2 
plasmid co-delivered in Balb/c mice
[16]. In the present 
study, HCcAg.120-pIDKE2 complexes were 
characterized at the ultrastructural level. Besides, novel 
elements about the immunogenicity of these protein-
DNA complexes, including the influence of adjuvant 
and administration route are described. 
 
MATERIALS AND METHODS 
 
Antigens and antibody: Endotoxin-free HCcAg.120 
was produced for research use only up to 90% of purity 
as previously described
[17]. Recombinant truncated E1 
(E1.339) and E2 (E2.680) proteins have been 
previously described
[18,19]. Particulate recombinant 
small surface antigen of hepatitis B virus (HBsAg) was 
produced with more than 95% of purity at the CIGB 
production facilities (CIGB, Cuba)
[20]. A mouse 
monoclonal antibody against the residues 580-600 of 
E2 (mAb SS-HepC.3) was used to detect E2.680 in 
immunoelectron microscopy experiments
[21].  
 
Plasmids:  pIDKE2
[22] is a plasmid for DNA 
immunization containing the gene-fragment coding for 
the first 650 aa of the HCV polyprotein (including 
HCcAg, E1 and E2). pAEC-K6 plasmid
[22] was used as 
negative control.  
 
Vaccinia viruses and cell lines: The recombinant 
vaccinia virus vvRE, that expresses aa 1-650 of HCV 
polyprotein, is a vaccinia virus derived from the 
Western Reserve (WR) strain of vaccinia virus
[23]. 
African green monkey kidney cells BSC-40
[24] were 
grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10 % FBS and were used 
for determination of vaccinia virus titer in mice ovaries.  
 
HCcAg.120-pIDKE2 plasmid interaction: In vitro 
protein-nucleic acid assembly reactions were carried 
out using conditions previously described
[15]. Briefly, 5 
µg of purified HCcAg.120 was mixed with an equal 
volume of pIDKE2 plasmid (50 µg). The reactions were 
incubated at 30 ºC for 10 min followed by 15 min on 
ice. 
 
Transmission electron microscopy (TEM): Either 
pIDKE2 plasmid or HCcAg.120-pIDKE2 complexes 
were processed for TEM using a negative stain/rotary 
shadow technique. Fifteen microliter drops of freshly 
prepared samples were placed on glow-discharged 
collodion/carbon-coated 400-mesh copper grids for 3 
min. The solution was wicked off with filter paper and 
grids were rinsed in double-distilled H2O and allowed 
to dry. Rotary shadowing was performed using 1 in. of 
0.008-inch Pt/Pd 80/20 wire at 12° angle. Grids were 
imaged in a Jeol JEM 2000EX electron microscope 
operated at 80 kV. 
 
Immunoelectron microscopy (IEM): The muscle 
tissue samples were fixed with 4% (v/v) 
paraformaldehyde containing 0.2% (v/v) glutaraldehyde 
in 0.1 M phosphate buffer (pH 7.3) at 4 ºC for 3 h and 
washed with 0.1 M phosphate buffer. Fixed cells were 
dehydrated as previously described
[21], embedded in 
Lowicryl and polymerized by exposure to ultraviolet 
light at room temperature for 72 h. Ultrathin sections of 
liver biopsies were incubated with anti-E2 mAb in 
phosphate buffer, for 45 min at RT. The sections were 
rinsed three times for 30 min at RT with 0.1% BSA in 
PBS (BSA-PBS) and incubated for 1 h at RT with gold-
labeled anti-mouse IgG (Amersham, England) diluted 
1:100 in BSA-PBS. As control, the primary antibody 
was substituted by normal mouse serum. All sections 
were stained with saturated uranyl acetate and lead 
citrate and examined with a JEOL/JEM 2000 EX 
transmission electron microscope (JEOL, Japan). 
 
Immunization schedule: HCcAg.120-pIDKE2 
complexes were used to induce specific immune 
responses in mice. On one hand, four groups of ten 
female Balb/c mice (6 to 8 weeks old) each, were 
immunized either intramuscularly (i.m.) or intranasal 
(i.n.) as follow: Group 1 was i.m. immunized with 
HCcAg.120-pIDKE2 (5 µg of HCcAg.120/50 µg of 
pIDKE2) in phosphate-buffered saline (PBS) solution 
(0.1 M NaCl, 2 mM KCl, 10 mM Na2HPO4, 1 mM 
KH2PO4 pH 7.4), Group 2 was i.m. immunized with 
HCcAg.120-pIDKE2 adsorbed to Aluminum 
Hydroxide (Alum), Group 3 was i.n. immunized with 
HCcAg.120-pIDKE2 in PBS, Group 4 was i.m. 
immunized with 50 µg of pAEC-K6 absorbed in 
Aluminum Hydroxide. All groups were boosted at 14 
and 28 days after primary immunization. Serum 
samples were taken before immunization and on day 42 
by retro-orbital punction. Splenocytes from 5 mice per 
group were isolated on day 42. Five animals per group 
received two additional doses of the respective 
immunogen at weeks 6 and 12 after primary 
immunization. These mice were challenged with a 
recombinant vaccinia virus expressing HCV Core, E1 
and E2 proteins, 2 weeks after the last immunization. 
 
Enzyme-linked immunosorbent assay (ELISA): The 
96-well microtiter plates (Costar, Cambridge, MA) 
were coated with 100 µL of either E1.339 (10 µg mL¯
1) 
or E2.680 (10 µg mL¯
1) diluted in coating buffer (50 
mM carbonate buffer, pH 9.6) at 4ºC overnight. After 
three washes with PBS containing 0.05 % Tween 20 
(PBST), the wells were blocked with 100 µl of PBST 
containing 1 % skim milk at room temperature for 1 
hour. Each well received 100 µl of the mice sera in 
PBST at serial two-fold dilutions (starting from 1:50) 
and the plates were incubated at 37ºC for 1 hour. Am. J. Immunol., 2 (3): 71-76, 2006 
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Subsequent steps were performed as previously 
described
[22]. The cut off value to consider a sample as 
positive was established as twice the mean absorbance 
(O.D) value of control mice sera (animals inoculated 
with pAEC-K6 absorbed in Alum) from three 
determinations. Antibody titer was considered as the 
maximal serum sample dilution rendering a positive 
reaction in ELISA.  
 
Lymphoproliferation assay: This assay has been 
described previously
[25]. Briefly, pools of spleen cells 
from five immunized mice per group were cultivated in 
triplicate by using 96-well round-bottom plates at 2x10
5 
cells per well in 200 µl of RPMI-1640 containing 10% 
heat-inactivated fetal calf serum (FCS), 2 mmol L¯
1 L-
glutamine, 50 units mL¯
1 penicillin and 50 µg mL¯
1 
streptomycin. Cells were stimulated with 5 µg mL¯
1 of 
either E1.339 or E2.680 in triplicate. As negative 
controls, effector cells were stimulated with either 
recombinant HBsAg or medium alone. Concanavalin A 
(5 µg mL¯
1) was used as positive control. After 
stimulation for 5 days, [
3H]thymidine was added (1 
µCi/well). Cells were incubated for an additional 6 
hours and the [
3H]thymidine incorporation into DNA 
was measured after harvesting the plates. Lymphocyte 
stimulation index (SI) was calculated as the mean 
counts per minute (cpm) measured after antigen 
stimulation divided by the mean cpm of cells incubated 
with medium alone. A SI of >3 was considered as 
positive. Splenocytes from unimmunized mice were 
analyzed as controls and they all showed a SI of <1.5. 
 
Vaccinia virus titer in the ovaries of challenged 
mice:  At 15 days after the final protein-DNA 
complexes administration, mice (5 per group) were 
challenged intraperitoneally with 10
6 plate forming 
units (pfu) of vaccinia virus expressing HCV structural 
proteins (vvRE). Five days after the challenge, mice 
were sacrificed and the ovaries were removed, 
homogenized, sonicated and assayed for viral titer by 
serial 10-fold dilutions on a plate of BSC-40 indicator 
cells. After 2 days of culture, the medium was removed, 
the BSC-40 cell monolayer was stained with 1 % 
crystal violet (Merck, Darmstadt, Germany) for 10 min 
and the number of plaques per well was counted.  
 
Statistical procedures: To compare differences among 
groups, a One-way ANOVA with the Newman-Keuls 
post-test or Kruskal-Wallis non-parametric statistic test 
with Dunn's Multiple Comparison Test as post-test 
were used. P<0.05 was considered significant. 
 
RESULTS 
 
TEM characterization of HCcAg.120-pIDKE2 
complexes:  Either pIDKE2 plasmid (arrowheads) or 
HCcAg.120-pIDKE2 complexes (arrows) were 
visualized in TEM using the negative stain/rotary 
shadow technique (Fig. 1). HCcAg.120-pIDKE2 
complexes forming heterogeneous packaged structures 
were observed (Fig. 1, arrow). The size ranged between 
80 nm and 300 nm. 
 
 
Fig. 1:  Transmission  electron microscopy image of 
HCcAg.120-pIDKE2 complexes using rotary 
shadowing technique. Arrows: HCcAg.120-
pIDKE2 complexes, arrowhead: pIDKE2 
plasmid. (Bar=200 nm) 
 
TEM characterization of HCV expression: HCV 
expressing cells are shown in Fig. 2. Seventy-two hours 
after inoculation of HCcAg.120-pIDKE2, E2 protein 
was immunolabeled in muscle cells. In addition, VLPs 
were rarely observed. These particles were scarcely 
detected and immunolabeled with anti-E2 antibodies 
(Fig. 2B, arrows). No immunolabeling was observed in 
muscle cells from non-immunized mice (Fig. 2A). 
 
Effect of the administration route and adjuvant on 
the immunogenicity of HCcAg.120-pIDKE2 
complexes: To evaluate the effect of the immunization 
route and adjuvant on the immunogenicity of 
HCcAg.120-pIDKE2 in mice, HCcAg.120-pIDKE2 
either in PBS or in Alum were i.m. or i.n. injected into 
Balb/c mice. Particularly, we focused on the immune 
response elicited against envelope antigens, since it is 
only generated after protein production occurs in vivo in 
cells incorporating functional pIDKE2 molecules. 
 
Total serum envelope-specific IgG response: 
Presence of anti-envelope antibodies (against E1 and 
E2) in immunized mice was detected by an anti-
envelope ELISA. The HCcAg.120-pIDKE2/Alum 
formulation induced the highest anti-E1 and anti-E2 
IgG responses (Fig. 3). These responses showed 
significant differences compared to that detected in 
mice immunized with HCcAg.120-pIDKE2/PBS by the 
i.n. route. However, no significant differences were 
observed with respect to the group immunized with 
HCcAg.120-pIDKE2/PBS by the i.m. route (Fig. 3).  
 
Envelope-specific lymphoproliferative responses: 
Strong anti-envelope proliferative responses were 
detected in splenocytes from all mice immunized with 
HCcAg.120-pIDKE2 (Fig. 4).  Am. J. Immunol., 2 (3): 71-76, 2006 
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Fig.  2:  Immunolabeling of E2 by IEM. A) Muscle cells 
from non-immunized mice, no immunostaining was 
observed using anti-E2 mAbs. B) Immunostaining 
with anti-E2 mAbs and gold-labeled anti-mouse 
IgG, detected E2 in muscle cells and VLPs. 
(Bar=200 nm)  
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Fig.  3:  Induction of humoral immune response by 
injection of HCcAg.120-pIDKE2 into Balb/c 
mice. Titters of either total E1-specific IgG (A) 
[b>a**, (**p<0.01)] or total E2-specific IgG (B) 
[b>a**, (**p<0.01)] response in sera of mice 
after immunization are shown. DNA: pIDKE2 
plasmid; im: intramuscularly; in: intranasally. 
Results are shown as the reciprocal of the serum 
dilution equivalent to twice the mean optical 
density (O.D.492 nm) of negative control. Errors 
bars indicating the standard errors of the means 
are shown. Stat: ** Kruskal-Wallis non-
parametric statistic test with Dunn's Multiple 
Comparison Test as post-test were used. P<0.05 
was considered significant 
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Fig.  4:  Proliferative responses of splenic lymphocytes 
from immunized mice. DNA: pIDKE2 plasmid; 
im: intramuscularly; in: intranasally. Data are 
shown as the mean SI. Errors bars indicating the 
standard errors of the means are shown. SI of ≥3 
is considered positive. Groups are indicated on 
the x-axis  
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Fig.  5:  Viremia control in a surrogate vaccinia virus 
challenge model. Results are shown as the mean 
logarithm of vvRE, a vaccinia virus expressing 
HCV structural antigens, in ovaries of 
immunized mice. Error bars indicate the standard 
deviation of the mean from 5 individual mice. 
Stat: * One-way ANOVA with the Newman-
Keuls post-test were used. P<0.05 was 
considered significant. b<a**, (**p<0.01) 
 
Note that there was a trend for the anti-E1 proliferative 
response to be higher than the anti-E2 proliferative 
response in all groups of immunized mice. In mice 
immunized with HCcAg.120-pIDKE2/PBS by the i.n. 
route, anti-E1 but not anti-E2 proliferative responses 
were detected. Remarkably, the anti-E1 proliferative 
response obtained in mice i.m. immunized with 
HCcAg.120-pIDKE2/PBS was at least two fold higher 
than that observed in the other groups of mice (Fig. 4). 
 
Viremia control in a vaccinia virus surrogate 
challenge model: Two weeks after the final 
immunization, five animals per group were challenged 
with a recombinant vaccinia virus expressing the HCV 
structural proteins. Only the administration of Am. J. Immunol., 2 (3): 71-76, 2006 
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HCcAg.120-pIDKE2/PBS by i.m. route could 
significantly contribute to viremia control in challenged 
mice (Fig. 5). Viral titer in ovaries of these mice was 
1.5 log lower (p<0.01) than the value detected in 
negative control animals (pAEC-K6/Alum group), 
although no statistical differences were observed with 
respect to groups immunized with HCcAg.120-pIDKE2 
in Alum or administered in PBS by i.n route.  
 
DISCUSSION 
 
  Recently, it has been shown that a truncated 
HCcAg variant, comprising the first 120 aa 
(HCcAg.120) of this antigen, with a 32 aa N-terminal 
fusion peptide (6xHistag-XpressTMepitope), interacts 
with nucleic acids
[15]. In fact, in vitro interaction 
between HCcAg.120 and pIDKE2 plasmid has been 
previously demonstrated by delayed electrophoretic 
mobility. Formation of large and heterogenous VLPs, 
characterized by a buoyant density of 1.30-1.34 g mL¯
1, 
has been described
[15]. 
  In the present study, HCcAg.120-pIDKE2 
complexes were visualized by TEM, showing the 
rounded shape of these complexes. In addition, HCV 
expression  in vivo was monitored by TEM. 
Immunolabeling of E2 indicates early expression of 
HCV proteins in muscle cells, after protein-DNA 
complexes inoculation in mice. Besides, VLPs with an 
average size of 40 nm were immunolabeled with anti-
E2 antibodies indicating the presence of E2 on the 
surface of such structures. However, it was very 
difficult to detect these particles, suggesting that the 
assembly process might be inefficient. 
  The HCV envelope proteins are believed to contain 
important epitopes
[7]. Therefore, many studies have 
focused on the induction of anti-envelope humoral and 
cellular immune responses in mice and 
monkeys
[19,22,26,27]. Our data show that HCcAg.120-
pIDKE2 complexes were immunogenic in vivo, 
inducing strong anti-HCV humoral and T cell 
proliferative immune responses, directed against 
envelope antigens. This is in agreement with a previous 
work, showing that mixtures of HCcAg and pIDKE2 
elicited stronger and more diverse humoral and cellular 
immunity than the immunization with the individual 
components in Balb/c mice
[16]. This kind of mixture 
also controlled the infection after the challenge with a 
recombinant vaccinia virus expressing the HCV core
[16]. 
In the present work, i.m injection of HCcAg.120-
pIDKE2 complexes induced viremia control after 
challenge with a recombinant vaccinia virus expressing 
HCV Core, E1 and E2. 
  It should be noted that HCcAg.120-pIDKE2 
administration by the i.n. route showed a trend to be 
less immunogenic than inoculation of HCcAg.120-
pIDKE2 by the i.m. route. Probably, immune response 
against antigens encoded by pIDKE2 is not correctly 
activated in mucosa since a previous study has 
demonstrated that individual administration of 
HCcAg.120 protein by the i.n. route induces strong 
immune responses in Balb/c mice
[20].  
  On the other hand, results shown here 
demonstrated that Alum enhanced the HCV-specific 
IgG antibody production after HCcAg.120-pIDKE2 
administration in mice. However, the analysis of the 
HCV-specific cellular immune response showed that 
HCcAg.120-pIDKE2 complexes delivered in PBS by 
the i.m. route induced the strongest HCV-specific 
lymphoproliferative response, especially against E1. 
This result might be suggesting that formulation of 
protein-DNA complexes in conjunction with Alum can 
not only enhance the specific anti-HCV antibody 
response, but also influence the bias of the immune 
response to a Th2 pattern. Previously, Kwissa et al. 
showed that a CTL response was not elicited when 
AlPO4 was used in formulations containing protein and 
a DNA vaccine
[28]. This is consistent with the observed 
failure in controlling vaccinia virus infection, in the 
surrogate challenge model, after administration of 
HCcAg.120-pIDKE2 formulated in Alum, in contrast to 
inoculation in PBS. Indeed, several evidences indicate 
that in the vaccinia virus challenge model, protective 
response is mainly mediated by the cellular immune 
response induced against the antigen shared by the virus 
and the immunogen used
[29-31].  
  Several human studies have presented evidence 
that a strong HCV-specific CD4+ T cell proliferative 
response is associated with either viral clearance in 
acute hepatitis C
[32-34] or in chronic HCV infection 
successfully treated with IFN
[35] or with a benign carrier 
state
[36,37]. The importance of HCV specific CD4+ T 
cell proliferative response in viral control has also been 
demonstrated in patients with HCV recurrence after 
loss of virus-specific CD4+ T cell response
[33]. In 
general, persons able to mount a strong cellular immune 
response are more likely to experience viral 
clearance
[13,37,38]. Therefore, our findings that 
HCcAg.120-pIDKE2 complexes can induce not only 
anti-HCV envelope antibodies, but strong cellular 
immunity, suggest their potential use as components of 
HCV vaccine candidates. Moreover, the ability of HCV 
Core protein for binding nucleic acids and forming 
protein-DNA complexes might be particularly useful 
for the development of DNA vaccine formulations 
against different pathogens. 
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